Ultragenyx Pharmaceutical (RARE) Gross Profit (2018 - 2026)

Ultragenyx Pharmaceutical (RARE) has reported Gross Profit for 9 consecutive years, with $106.0 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Gross Profit fell 3.64% year-over-year to $106.0 million; the TTM figure through Mar 2026 stood at $559.4 million (up 11.49% YoY), while the FY2025 annual figure was $564.0 million, up 16.77% from the prior year.
• Gross Profit retreated to $106.0 million in Q1 2026 per RARE's latest filing, from $177.9 million in the prior quarter.
• Across five years, Gross Profit topped out at $177.9 million in Q4 2025 and bottomed at $73.8 million in Q1 2022.
• Historically, Gross Profit has averaged $110.4 million across 5 years, with a median of $106.0 million in 2026.
• Annual changes were most pronounced in 2022 — Gross Profit retreated 21.62% — and 2024, when it surged 36.07%.
• Ultragenyx Pharmaceutical's Gross Profit stood at $98.0 million in 2022, then rose by 17.62% to $115.3 million in 2023, then climbed by 27.91% to $147.5 million in 2024, then advanced by 20.65% to $177.9 million in 2025, then plunged by 40.43% to $106.0 million in 2026.
• Business Quant data shows RARE's Gross Profit at $106.0 million in Q1 2026, $177.9 million in Q4 2025, and $131.9 million in Q3 2025.